GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PharmX Technologies Ltd (ASX:PHX) » Definitions » EV-to-EBITDA

PharmX Technologies (ASX:PHX) EV-to-EBITDA : 7.91 (As of Apr. 27, 2024)


View and export this data going back to 1973. Start your Free Trial

What is PharmX Technologies EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmX Technologies's enterprise value is A$5.81 Mil. PharmX Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.73 Mil. Therefore, PharmX Technologies's EV-to-EBITDA for today is 7.91.

The historical rank and industry rank for PharmX Technologies's EV-to-EBITDA or its related term are showing as below:

ASX:PHX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -154.26   Med: 5.74   Max: 68.58
Current: 7.9

During the past 13 years, the highest EV-to-EBITDA of PharmX Technologies was 68.58. The lowest was -154.26. And the median was 5.74.

ASX:PHX's EV-to-EBITDA is ranked better than
74.62% of 461 companies
in the Healthcare Providers & Services industry
Industry Median: 13.17 vs ASX:PHX: 7.90

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), PharmX Technologies's stock price is A$0.03. PharmX Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.004. Therefore, PharmX Technologies's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


PharmX Technologies EV-to-EBITDA Historical Data

The historical data trend for PharmX Technologies's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmX Technologies EV-to-EBITDA Chart

PharmX Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.18 30.30 30.61 40.26 -14.03

PharmX Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 40.26 - -14.03 -

Competitive Comparison of PharmX Technologies's EV-to-EBITDA

For the Health Information Services subindustry, PharmX Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmX Technologies's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's EV-to-EBITDA falls into.



PharmX Technologies EV-to-EBITDA Calculation

PharmX Technologies's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=5.805/0.734
=7.91

PharmX Technologies's current Enterprise Value is A$5.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmX Technologies's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmX Technologies  (ASX:PHX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

PharmX Technologies's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.03/-0.004
=At Loss

PharmX Technologies's share price for today is A$0.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmX Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.004.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


PharmX Technologies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PharmX Technologies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmX Technologies (ASX:PHX) Business Description

Traded in Other Exchanges
N/A
Address
17 Castlereagh Street, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd Formerly Corum Group Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business. the company discontinued the e-commerce business in 2022.